Equities Analysts Set Expectations for TERN FY2030 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Analysts at HC Wainwright issued their FY2030 EPS estimates for Terns Pharmaceuticals in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($1.60) per share for the year. HC Wainwright currently has a “Neutral” rating and a $53.00 target price on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share.

A number of other analysts have also recently commented on TERN. BMO Capital Markets lifted their price target on Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Barclays raised their price objective on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. UBS Group upgraded Terns Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 4th. Citizens Jmp downgraded shares of Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a report on Thursday. Finally, Wall Street Zen lowered shares of Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $56.90.

Terns Pharmaceuticals Price Performance

NASDAQ TERN opened at $52.92 on Thursday. The stock’s fifty day moving average price is $41.28 and its 200 day moving average price is $29.06. Terns Pharmaceuticals has a 1 year low of $1.87 and a 1 year high of $53.19. The company has a market cap of $5.49 billion, a price-to-earnings ratio of -51.38 and a beta of -0.31.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several institutional investors have recently made changes to their positions in TERN. Avoro Capital Advisors LLC purchased a new stake in Terns Pharmaceuticals during the fourth quarter worth $175,740,000. Seven Fleet Capital Management LP acquired a new stake in Terns Pharmaceuticals during the fourth quarter valued at $1,491,000. Invesco Ltd. increased its holdings in Terns Pharmaceuticals by 26.9% in the fourth quarter. Invesco Ltd. now owns 606,247 shares of the company’s stock valued at $24,492,000 after buying an additional 128,573 shares in the last quarter. Mackenzie Financial Corp purchased a new position in Terns Pharmaceuticals in the fourth quarter valued at $215,000. Finally, NewEdge Advisors LLC raised its position in shares of Terns Pharmaceuticals by 240.0% in the fourth quarter. NewEdge Advisors LLC now owns 9,173 shares of the company’s stock worth $371,000 after acquiring an additional 6,475 shares during the period. 98.26% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the transaction, the chief executive officer directly owned 138,976 shares of the company’s stock, valued at approximately $5,294,985.60. The trade was a 33.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 170,409 shares of company stock valued at $6,563,769. Insiders own 1.50% of the company’s stock.

More Terns Pharmaceuticals News

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to acquire Terns for about $6.7 billion in cash, bringing a late‑stage leukemia candidate into MRK’s oncology lineup—this deal narrative is the primary bullish catalyst supporting a sharp rally toward the $53 offer price. Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers
• Positive Sentiment: Analysts and news outlets emphasize Merck’s acquisition as strategic—adding a leukemia asset as Keytruda faces patent pressure—supporting upside sentiment for TERN shares. Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
• Positive Sentiment: Market commentary notes a possible bidding‑war dynamic after the Merck approach, which can lift the stock above the announced offer if other suitors emerge. Merck’s deal for Terns sparks debate over a possible biotech bidding war
• Positive Sentiment: Market reaction has pushed TERN to a new 52‑week high as investors price in the deal and potential takeover premium. Terns Pharmaceuticals (NASDAQ:TERN) Hits New 52-Week High – Still a Buy?
• Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating and published FY2030 estimates and a $53.00 price target—its view aligns with the announced cash price, leaving limited analyst upside ahead of deal closure. HC Wainwright Reaffirms Neutral Rating for Terns Pharmaceuticals (NASDAQ:TERN)
• Negative Sentiment: Unusually large put option activity was reported (7,719 puts, a ~96% increase vs. typical put volume), suggesting some traders are hedging or positioning for downside/uncertainty around deal terms or timing.
• Negative Sentiment: A shareholder law firm (Kahn Swick & Foti) opened an investigation into the adequacy of the $53 per‑share price and the sale process, which could lead to litigation or delay and adds execution risk. Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. – TERN
• Negative Sentiment: Several brokers trimmed coverage or lowered stances to “Hold” (Citizens/JMP, TD Cowen), reducing near‑term buy-side reinforcement; TD Cowen’s $53 target effectively prices the deal in with little upside. Benzinga

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.